recombinant apn  (R&D Systems)

Journal: NPJ Regenerative Medicine

Article Title: Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis

doi: 10.1038/s41536-021-00132-4

Figure Lengend Snippet: a In γ-sEVs, the levels of proteins including annexin A1, lactotransferrin, and aminopeptidase N increased. These γ-sEVs induce the counts of anti-inflammatory macrophages with high motility and phagocytic ability, which increase repair of damaged tissue. In addition, these γ-sEVs induce regulatory T cell counts in the liver. These processes are related to fibrolysis. b The γ-sEVs also possess the ability to reduce inflammation; however, they do not prevent HSC activation, suggesting that γ-sEVs indirectly reduce fibrogenesis by reducing inflammation. HSCs, hepatic stellate cells.

Article Snippet: Recombinant human annexin A1 (Abcam, Cambridge, UK; final concentration 100 ng/ml), recombinant galectin-3 binding protein (LG3BP) (Aviva Systems Biology, San Diego, CA, USA; final concentration 1 ng/ml), recombinant human lactoferrin (lactotransferrin) (Abcam; final concentration 0.1 ng/ml), recombinant human lactadherin (MFGE8) (R & D Systems, Inc.; final concentration 100 ng/ml), and recombinant human aminopeptidase N/CD13 (R & D Systems; final concentration 100 ng/ml) were used.

Techniques: Activation Assay